Donald C. Goff

Original Research

Attitudes of Schizophrenia Outpatients Toward Psychiatric Medications: Relationship to Clinical Variables and Insight

Original Research

Clozapine, Diabetes Mellitus, Hyperlipidemia, and Cardiovascular Risks and Mortality: Results of a 10-Year Naturalistic Study

Letter to the Editor

Colon Perforation and Peritonitis Associated With Clozapine

Consensus Statement

Consensus on Monitoring Blood Antipsychotic Levels

The quantification of antipsychotic levels in blood, or therapeutic drug monitoring (TDM), could aid clinicians in numerous challenging scenarios. Learn more about using TDM for dosing decisions in this...

Original Research

Elevated Hemoglobin A1c as a Possible Indicator of Diabetes Mellitus and Diabetic Ketoacidosis in Schizophrenia Patients Receiving Atypical Antipsychotics

Original Research

Two-Year Follow-Up of a Smoking Cessation Trial in Patients With Schizophrenia: Increased Rates of Smoking Cessation and Reduction.

Original Research

Independent Effects of Tobacco Abstinence and Bupropion on Cognitive Function in Schizophrenia

Article

SGAs and Private Psychiatry Practices

Read how private psychiatry practices should respond to and manage SGA-related adverse effects of patients.

Original Research

Medical Morbidity and Mortality in Schizophrenia: Guidelines for Psychiatrists

Original Research

Modafinil for Clozapine-Treated Schizophrenia Patients: A Double-Blind, Placebo-Controlled Pilot Trial

Original Research

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of Adjunctive Aripiprazole for Schizophrenia or Schizoaffective Disorder Inadequately Treated With Quetiapine or Risperidone Monotherapy

Letter to the Editor

Polypharmacy in Schizophrenia: A Fuzzy Concept

Original Research

Predictors of Early Abstinence in Smokers With Schizophrenia

Original Research

Risperidone Added to Clozapine: Impact on Serum Prolactin Levels

Article

Strategies for Improving Treatment Adherence in Schizophrenia and Schizoaffective Disorder

Original Research

Switching From Clozapine to Olanzapine in Treatment-Refractory Schizophrenia: Safety, Clinical Efficacy, and Predictors of Response

Letter to the Editor

Varenicline Treatment for Smokers With Schizophrenia: A Case Series

Educational Activity

Treatment Adherence in Schizophrenia and Schizoaffective Disorder

Letter to the Editor

A Case of Dramatic Improvement of Severe Tardive Dyskinesia After Switch to Aripiprazole

Educational Activity

Mental Illnesses and Private Practices

Read how private psychiatrists should help mental illness patients maintain their physical health, including monitoring for weight gain and cardiac risk factors.

Original Research

Glucose Metabolism in Patients With Schizophrenia Treated With Olanzapine or Quetiapine: A Frequently Sampled Intravenous Glucose Tolerance Test and Minimal Model Analysis

Attitudes of Schizophrenia Outpatients Toward Psychiatric Medications: Relationship to Clinical Variables and Insight

Clozapine, Diabetes Mellitus, Hyperlipidemia, and Cardiovascular Risks and Mortality: Results of a 10-Year Naturalistic Study

Colon Perforation and Peritonitis Associated With Clozapine

Consensus on Monitoring Blood Antipsychotic Levels

Elevated Hemoglobin A1c as a Possible Indicator of Diabetes Mellitus and Diabetic Ketoacidosis in Schizophrenia Patients Receiving Atypical Antipsychotics

Two-Year Follow-Up of a Smoking Cessation Trial in Patients With Schizophrenia: Increased Rates of Smoking Cessation and Reduction.

Independent Effects of Tobacco Abstinence and Bupropion on Cognitive Function in Schizophrenia

SGAs and Private Psychiatry Practices

Medical Morbidity and Mortality in Schizophrenia: Guidelines for Psychiatrists

Modafinil for Clozapine-Treated Schizophrenia Patients: A Double-Blind, Placebo-Controlled Pilot Trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of Adjunctive Aripiprazole for Schizophrenia or Schizoaffective Disorder Inadequately Treated With Quetiapine or Risperidone Monotherapy

Polypharmacy in Schizophrenia: A Fuzzy Concept

Predictors of Early Abstinence in Smokers With Schizophrenia

Risperidone Added to Clozapine: Impact on Serum Prolactin Levels

Strategies for Improving Treatment Adherence in Schizophrenia and Schizoaffective Disorder

Switching From Clozapine to Olanzapine in Treatment-Refractory Schizophrenia: Safety, Clinical Efficacy, and Predictors of Response

Varenicline Treatment for Smokers With Schizophrenia: A Case Series

Treatment Adherence in Schizophrenia and Schizoaffective Disorder

A Case of Dramatic Improvement of Severe Tardive Dyskinesia After Switch to Aripiprazole

Mental Illnesses and Private Practices

Glucose Metabolism in Patients With Schizophrenia Treated With Olanzapine or Quetiapine: A Frequently Sampled Intravenous Glucose Tolerance Test and Minimal Model Analysis

ELSEWHERE:

FOLLOW US:

Donald C. Goff

Attitudes of Schizophrenia Outpatients Toward Psychiatric Medications: Relationship to Clinical Variables and Insight

Clozapine, Diabetes Mellitus, Hyperlipidemia, and Cardiovascular Risks and Mortality: Results of a 10-Year Naturalistic Study

Colon Perforation and Peritonitis Associated With Clozapine

Consensus on Monitoring Blood Antipsychotic Levels

Elevated Hemoglobin A1c as a Possible Indicator of Diabetes Mellitus and Diabetic Ketoacidosis in Schizophrenia Patients Receiving Atypical Antipsychotics

Two-Year Follow-Up of a Smoking Cessation Trial in Patients With Schizophrenia: Increased Rates of Smoking Cessation and Reduction.

Independent Effects of Tobacco Abstinence and Bupropion on Cognitive Function in Schizophrenia

SGAs and Private Psychiatry Practices

Medical Morbidity and Mortality in Schizophrenia: Guidelines for Psychiatrists

Modafinil for Clozapine-Treated Schizophrenia Patients: A Double-Blind, Placebo-Controlled Pilot Trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of Adjunctive Aripiprazole for Schizophrenia or Schizoaffective Disorder Inadequately Treated With Quetiapine or Risperidone Monotherapy

Polypharmacy in Schizophrenia: A Fuzzy Concept

Predictors of Early Abstinence in Smokers With Schizophrenia

Risperidone Added to Clozapine: Impact on Serum Prolactin Levels

Strategies for Improving Treatment Adherence in Schizophrenia and Schizoaffective Disorder

Switching From Clozapine to Olanzapine in Treatment-Refractory Schizophrenia: Safety, Clinical Efficacy, and Predictors of Response

Varenicline Treatment for Smokers With Schizophrenia: A Case Series

Treatment Adherence in Schizophrenia and Schizoaffective Disorder

A Case of Dramatic Improvement of Severe Tardive Dyskinesia After Switch to Aripiprazole

Mental Illnesses and Private Practices

Glucose Metabolism in Patients With Schizophrenia Treated With Olanzapine or Quetiapine: A Frequently Sampled Intravenous Glucose Tolerance Test and Minimal Model Analysis

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles